Adults with severe depression who haven't responded to multiple treatments will continue to face limited options on the NHS after health chiefs rejected a promising new nasal spray antidepressant. The National Institute for Health and Care Excellence (NICE) has ruled that esketamine, despite showing significant promise in clinical trials, doesn't offer sufficient long-term benefits to justify its cost to the health service.
Esketamine, marketed under the brand name Spravato, is a derivative of ketamine and is administered as a nasal spray alongside a daily oral antidepressant. The treatment is specifically designed for adults with severe depression who haven't responded to at least two other antidepressant courses. Clinical trials have demonstrated it can lead to a significant reduction in depressive symptoms for some patients, offering hope for those with treatment-resistant depression.
However, NICE's appraisal committee expressed reservations about the drug's overall cost-effectiveness, particularly citing uncertainty surrounding its efficacy and benefits over longer periods. This cautious approach reflects the NHS watchdog's responsibility to ensure treatments provide value for money across the health service.
The manufacturer, Janssen—a pharmaceutical company of Johnson & Johnson—expressed disappointment with the decision. They highlighted the urgent need for new and effective treatment options for individuals living with treatment-resistant depression, a severe form of the condition that significantly impacts quality of life and can be debilitating. Janssen stated they would continue working with NICE to explore pathways for patients to access this treatment.
Mental health charities and patient advocacy groups have voiced concerns about the implications of NICE's decision. They argue that limiting access to innovative treatments restricts options for patients who have exhausted conventional therapies and are desperately seeking relief. The lack of new, effective treatments for severe and resistant depression remains a significant challenge within mental healthcare provision across the UK.
For those affected, this decision means esketamine will not be available as a routine treatment option through GPs or mental health services on the NHS in England and Wales. This could mean continued struggles for patients who haven't found success with existing medications, potentially affecting their ability to work, maintain relationships, and live fulfilling lives. However, patients should continue working with their healthcare teams, as other treatment combinations and approaches may still provide relief.
The Government, through the Department of Health and Social Care, regularly outlines its commitment to improving mental health services. However, decisions by independent bodies like NICE are based on clinical effectiveness and economic viability. The Labour Party, in opposition, has frequently criticised what they perceive as underfunding in mental health services, often calling for greater investment in new treatments and accessible therapies to address the growing mental health crisis.